Sessile serrated lesions
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Consecutive patients treated with CSP or EMR and histopathologically diagnosed with SSL at the Southern-Tohoku General Hospital in Fukushima, Japan, between January 2019 and December 2022 were included in this study. SSLs less than 10 mm in diameter by endoscopic measurement and achieved en-block resection were included in this study.
Exclusion criteria
Exclusion criteria: Exclusion criteria were as follows: cases with more than 6 resections; underwent piecemeal resection; advanced cancer coexistence; serious comorbidities; history of inflammatory bowel disease; difficulty obtaining consent due to psychiatric disorder.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The rate of histopathological positive vertical margin of CSP and EMR specimens. | — |
Secondary
| Measure | Time frame |
|---|---|
| Mucosal fragmentation, presence of lateral margin, histopathological positive lateral margin, presence of damage or thermal coagulation, presence of muscularis mucosae, presence of submucosa, and the recurrence rate associated with polyp resection methods. | — |
Countries
Japan
Contacts
Southern-Tohoku General Hospital Department of Gastroenterology